Vertex Pharmaceuticals Incorporated (VRTX)
NASDAQ
Closed
Aug 24, 2026
Day's Range
542.8952 wk Range
374.17Overview - VRTX - Vertex Pharmaceuticals Incorporated
Key Statistics
Valuation
Enterprise Value
133.03B
P/E (Trailing)
‪31.95‬
P/E (Forward)
‪24.92‬
PEG Ratio
‪4.01‬
Price / Sales (TTM)
‪11.03‬
Price / Book
‪6.85‬
EV / EBITDA
‪26.08‬
Profitability
Gross Margin
‪85.32%‬
Profit Margin
‪34.99%‬
Operating Margin
‪38.05%‬
Return on Assets
‪11.92%‬
Return on Equity
‪23.54%‬
Ownership
Shares Outstanding
253.34M
Float
252.68M
Short % of Shares Outstanding
‪1.76%‬
Held by Insiders
‪0.21%‬
Held by Institutions
‪98.12%‬
Price stats
Beta
‪0.30‬
50-Day Avg
‪490.86‬
200-Day Avg
‪459.97‬
Dividends
Payout Ratio
‪0.00%‬
Analyst Consensus
29 analysts
Average price target
‪$ 563.12‬Shariah Compliance
Report Date: Feb 16, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - VRTX - Vertex Pharmaceuticals Incorporated
Peers - VRTX - Vertex Pharmaceuticals Incorporated
Peer Comparison
Compared with companies in Biotechnology listed on NASDAQ.
- VRTXNASDAQVertex Pharmaceuticals Incorporated136.84BMarket Cap+26.86%52-week change30.76P/E (Trailing)‪34.99%‬Profit Margin
- ARGXNASDAQargenx SE American Depositary Receipt65.04BMarket Cap+34.86%52-week change39.69P/E (Trailing)‪32.26%‬Profit Margin
- ALNYNASDAQAlnylam Pharmaceuticals Inc31.60BMarket Cap-87.81%52-week change41.15P/E (Trailing)‪16.12%‬Profit Margin
- BNTXNASDAQBioNTech SE29.28BMarket Cap+9.87%52-week change160.80P/E (Trailing)‪-63.63%‬Profit Margin
- ASNDNASDAQAscendis Pharma A/S16.61BMarket Cap+24.84%52-week change19.38P/E (Trailing)‪70.84%‬Profit Margin
- BBIONASDAQBridgeBio Pharma, Inc.15.93BMarket Cap+41.98%52-week change-21.56P/E (Trailing)‪-97.02%‬Profit Margin
- BMRNNASDAQBiomarin Pharmaceutical Inc.12.91BMarket Cap+12.29%52-week change180.27P/E (Trailing)‪2.14%‬Profit Margin
Profile Summary - VRTX - Vertex Pharmaceuticals Incorporated
About
Vertex Pharmaceuticals Incorporated is a global biopharmaceutical company headquartered in Boston, Massachusetts, specializing in the discovery, development, and commercialization of transformative medicines for patients with serious diseases. The company's primary focus centers on cystic fibrosis, where it has…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
